{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:21Z","timestamp":1792800921199,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BMFTR","award":["(#01EO2101)"],"award-info":[{"award-number":["(#01EO2101)"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaplastic ependymoma is a rare and aggressive central nervous system malignancy for which effective systemic treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody\u2013drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated intracranial activity in patients with HER2-positive solid tumors. We report two patients with recurrent, heavily pretreated anaplastic ependymoma and molecular evidence of HER2 activation who received T-DXd as off-label therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Both patients underwent comprehensive molecular profiling, including whole-genome and transcriptome sequencing and proteomic analyses. HER2 expression was subsequently assessed by immunohistochemistry. Treatment response was evaluated by serial magnetic resonance imaging (MRI), while clinical benefit and treatment-related toxicities were documented longitudinally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both patients had multiply recurrent anaplastic ependymoma and had exhausted conventional local and systemic treatment options. Molecular profiling identified elevated ERBB2 expression at the transcriptomic and\/or proteomic level, with HER2 immunohistochemical positivity in approximately 80% and 15% of tumor cells, respectively. The first patient received T-DXd and achieved sustained disease stabilization after an initial mixed radiographic response, with ongoing disease control for 26\u00a0months. The second patient initially received temozolomide plus lapatinib but experienced progressive disease. Following treatment with T-DXd disease stabilization was achieved and maintained for 14\u00a0months at the most recent follow-up. Treatment-related hematologic and hepatic toxicities were manageable with supportive measures, dose modification, and temporary treatment interruption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These two cases demonstrate durable disease stabilization with T-DXd in heavily pretreated patients with recurrent anaplastic ependymoma and molecular evidence of HER2 activation. The clinical benefit observed, including after failure of lapatinib-based HER2-targeted therapy, supports further investigation of T-DXd in molecularly selected patients with recurrent ependymoma. Comprehensive molecular profiling may help identify patients who could benefit from HER2-directed treatment in this rare and therapeutically challenging disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40348-026-00263-y","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:39:52Z","timestamp":1791344392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Dietmar","family":"Krex","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Kerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Grey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Plei\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Fr\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Folprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia S.","family":"Link-Rachner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"263_CR1","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N et al (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22:5097\u20135108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822","journal-title":"Clin Cancer Res"},{"key":"263_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/nejmoa2203690","journal-title":"N Engl J Med"},{"key":"263_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08708-5","volume":"21","author":"MD Hackshaw","year":"2021","unstructured":"Hackshaw MD, Danysh HE, Henderson M, Wang E, Tu N, Islam Z et al (2021) Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. BMC Cancer 21:1\u201316. https:\/\/doi.org\/10.1186\/s12885-021-08708-5","journal-title":"BMC Cancer"},{"issue":"1","key":"263_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0082-6","volume":"5","author":"H Kurihara","year":"2015","unstructured":"Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K et al (2015) 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res 5(1):8. https:\/\/doi.org\/10.1186\/s13550-015-0082-6","journal-title":"EJNMMI Res"},{"key":"263_CR5","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/RLI.0b013e318226c427","volume":"46","author":"DB Percy","year":"2011","unstructured":"Percy DB, Ribot EJ, Chen Y, McFadden C, Simedrea C, Steeg PS et al (2011) In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol 46:718\u2013725. https:\/\/doi.org\/10.1097\/RLI.0b013e318226c427","journal-title":"Invest Radiol"},{"key":"263_CR6","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.1016\/j.annonc.2023.09.554","volume":"34","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Modi S, Li W, Park YH, Chung W, Kim S-B et al (2023) 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. Ann Oncol 34:S335\u2013S336. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.554","journal-title":"Ann Oncol"},{"key":"263_CR7","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G et al (2024) Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med 30:3717\u20133727. https:\/\/doi.org\/10.1038\/s41591-024-03261-7","journal-title":"Nat Med"},{"key":"263_CR8","doi-asserted-by":"publisher","unstructured":"Achey RL, Vo S, Cioffi G, Gittleman H, Schroer J, Khanna V, et al (2020) Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016. Neuro-Oncology Practice. Oxford University Press. pp. 549\u2013558. https:\/\/doi.org\/10.1093\/nop\/npaa023","DOI":"10.1093\/nop\/npaa023"},{"key":"263_CR9","doi-asserted-by":"publisher","unstructured":"Armstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, et al (2018) Rare-24. Objective response and clinical benefit in recurrent ependymoma in adults: final report of Cern 08\u201302: a phase II study of dose-dense temozolomide and lapatinib. Neuro Oncol 20:241\u2013241. https:\/\/doi.org\/10.1093\/neuonc\/noy148.998","DOI":"10.1093\/neuonc\/noy148.998"},{"key":"263_CR10","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, H\u00fcllein J et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11:2780\u20132795. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0126","journal-title":"Cancer Discov"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-026-00263-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00263-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:39:53Z","timestamp":1791344393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40348-026-00263-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1186\/s40348-026-00263-y","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"21 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"50"}}